Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYMPHOSEEK KIT vs ALORA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
For lymphoscintigraphy to assist in the localization of sentinel lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prostate cancer (palliative),Breast cancer (palliative, in selected cases),Postpartum breast engorgement (prevention)
Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Technetium Tc-99m tilmanocept is not metabolized; it is cleared from the injection site via the lymphatic system and excreted renally.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates).
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Negligible (<5%), primarily to albumin.
Estradiol is approximately 97-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The binding to SHBG is high affinity, while albumin binding is nonspecific and lower affinity.
Approximately 0.2 L/kg, indicating distribution within extracellular fluid.
The apparent volume of distribution (Vd) of estradiol is approximately 5-10 L/kg, indicating extensive distribution into tissues including breast, adipose, and reproductive organs. This large Vd reflects sequestration in adipose tissue and other estrogen-sensitive tissues.
Not applicable (administered parenterally).
The bioavailability of estradiol from the transdermal system is approximately 10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. The absolute bioavailability relative to intravenous is near 100%, as transdermal delivery provides direct systemic absorption.
No dose adjustment required based on GFR, but ensure adequate hydration.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). Not studied in severe impairment (GFR <30 m L/min); use with caution.
No specific guidelines available; use with caution in severe hepatic impairment.
Contraindicated in severe hepatic disease (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use lowest effective dose and monitor. No adjustment for mild (Child-Pugh class A).
Not established; safety and efficacy in pediatric patients have not been studied.
Not approved for use in pediatric patients. Safety and efficacy not established.
No specific dosage adjustment; monitor for adverse effects as elderly may have reduced immune response.
Use lowest effective dose and duration. Consider increased risk of cardiovascular events, thromboembolism, and malignancy. Starting dose 0.025 mg/day with gradual titration as needed.
This drug does not have a black box warning.
Estrogens increase the risk of endometrial cancer. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures, including endometrial sampling if indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Risk of hypersensitivity reactions including anaphylaxis.,Not for intrathecal administration.,Radiation exposure risk.
Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women ≥65 years), breast cancer, endometrial cancer, gallstones, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, and exacerbation of endometriosis.
Known hypersensitivity to tilmanocept or any component of the formulation.
Undiagnosed abnormal genital bleeding, known/suspected pregnancy, known/suspected breast cancer (except in selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease, known protein C/protein S/antithrombin deficiency or other thrombophilic disorders, liver dysfunction or disease, known hypersensitivity to estradiol or any component.
No known food interactions. No dietary restrictions required.
No significant food interactions. Avoid grapefruit juice if on hormonal therapy as it may increase estrogen levels.
Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended doses. However, if administered intravenously, radiation exposure to the fetus could occur. No teratogenic effects are expected from the non-radioactive component (tilmanocept). Pregnancy category not assigned by FDA for diagnostic radiopharmaceuticals. Use only if clearly needed.
ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in female offspring, as well as congenital anomalies including cardiac defects and limb reduction defects. Second and third trimesters: increased risk of fetal genital abnormalities and potential for long-term reproductive tract effects. Estrogens are not indicated for use during pregnancy.
It is unknown whether tilmanocept is excreted in human milk. Because of the low dose and local administration, systemic exposure is minimal. However, to minimize radiation exposure to the nursing infant, temporary cessation of breastfeeding for 4-6 hours after administration is recommended. M/P ratio not available.
Estradiol is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. ALORA may reduce milk production and quality due to estrogenic effects. Use during breastfeeding is not recommended. If used, monitor the infant for signs of estrogen exposure such as breast enlargement or vaginal bleeding.
No dose adjustment necessary. The administered activity of technetium Tc 99m tilmanocept is typically 18.5-74 MBq (0.5-2.0 m Ci) regardless of pregnancy. Pharmacokinetic changes in pregnancy are not expected to require dose modification due to local subcutaneous administration.
ALORA is contraindicated in pregnancy; no dosing adjustments are applicable. The physiological increase in estrogen-binding proteins and hepatic clearance during pregnancy would theoretically reduce efficacy if used, but use is prohibited due to teratogenicity.
Lymphoseek (technetium Tc 99m tilmanocept) is a receptor-targeted radiotracer for sentinel lymph node mapping. Administer intradermally, subcutaneously, or peritumorally. Optimal imaging time: 15-60 min post-injection. Can be used in patients with penicillin allergy as it contains no penicillin. Ensure patient is not pregnant or lactating. May cause injection site reactions.
ALORA 0.03% estradiol vaginal cream is indicated for atrophic vaginitis. Apply 1-2 g daily for 2 weeks, then taper. May cause endometrial hyperplasia if used without progestin in women with intact uterus. Avoid in breast cancer history.
This is a radioactive dye used to find lymph nodes during surgery.,You will receive a small injection near the tumor site.,The procedure is generally safe, but inform your doctor if you are pregnant or breastfeeding.,You may experience mild pain, redness, or swelling at the injection site.,No special dietary restrictions are needed before the procedure.
Use the measured applicator for correct dose.,Apply cream at bedtime for best absorption.,Wash applicator after each use with soap and water.,Report any abnormal vaginal bleeding immediately.,Do not use if allergic to estrogens.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYMPHOSEEK KIT vs ALORA, answered by our medical review team.
LYMPHOSEEK KIT is a Radiopharmaceutical Diagnostic Agent that works by Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.. ALORA is a Estrogen that works by Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYMPHOSEEK KIT and ALORA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYMPHOSEEK KIT is: Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.. The standard adult dose of ALORA is: Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYMPHOSEEK KIT and ALORA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYMPHOSEEK KIT is classified as Category C. Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended d. ALORA is classified as Category C. ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.